SMS抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 293T cell lysate, Primary antibody: P02682(SMS Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P02682(SMS Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

SMS antibodies target sphingomyelin synthase (SMS), a key enzyme in sphingolipid metabolism that catalyzes the conversion of ceramide and phosphatidylcholine into sphingomyelin and diacylglycerol. Sphingomyelin is a critical component of cell membranes, while its metabolic byproducts, such as ceramide and sphingosine-1-phosphate, function as bioactive signaling molecules involved in cell proliferation, apoptosis, and stress responses. Dysregulation of SMS activity has been linked to metabolic disorders, cancer, and neurodegenerative diseases, driving interest in developing SMS-specific antibodies for research and therapeutic purposes.

These antibodies enable the detection, localization, and quantification of SMS isoforms (SMS1 and SMS2) in cellular and tissue samples, aiding studies on their distinct roles in lipid homeostasis and disease mechanisms. For example, SMS1 is primarily localized in the Golgi apparatus, while SMS2 associates with the plasma membrane, reflecting divergent biological functions. Recent advances in monoclonal antibody technology have improved specificity and sensitivity, supporting applications in immunohistochemistry, Western blotting, and flow cytometry.

Research utilizing SMS antibodies has highlighted their potential as biomarkers or therapeutic targets, particularly in cancers where altered sphingolipid metabolism promotes tumor survival. Further exploration of SMS inhibition or modulation via antibody-based strategies could offer novel treatments for metabolic and oncological conditions.